Tralokinumab-ldrm injection
Tralokinumab-ldrm injection is a targeted biologic therapy used to treat moderate-to-severe atopic dermatitis (eczema) in adults and adolescents 12 and older when prescription topical treatments haven't worked well enough.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Tralokinumab-ldrm injection: Patient Information Guide
A plain-language walkthrough of Tralokinumab-ldrm injection — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Tralokinumab-ldrm injection (brand name Adbry) is approved for the following use:
- Adbry treats moderate-to-severe atopic dermatitis (chronic eczema with significant skin inflammation) in adults whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable
- Adbry treats moderate-to-severe atopic dermatitis in adolescents 12 to 17 years of age whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable
- Adbry may be used with or without topical corticosteroids (steroid creams or ointments)
- Adbry is not approved for children younger than 12 years of age
⚙️How it works▾
Tralokinumab-ldrm is a monoclonal antibody — a lab-made protein designed to lock onto a very specific target. It binds to interleukin-13 (IL-13), a naturally occurring signaling molecule (called a cytokine) that plays a central role in the Type 2 immune response driving atopic dermatitis. By blocking IL-13 from connecting to its receptors on cells, tralokinumab-ldrm prevents the chain reaction that causes inflammation, skin barrier damage, and the release of other inflammatory chemicals (including IgE and chemokines) involved in eczema flares.
💊How it's taken▾
Adbry is given as a subcutaneous injection (under the skin) — not by mouth or into a vein. Adults start with a higher loading dose, then move to a maintenance dose given every other week; some adults who achieve clear or nearly clear skin after 16 weeks may be eligible for a less frequent schedule (every 4 weeks), depending on their body weight and response. Adolescents 12 to 17 follow a lower-dose schedule, also given every other week, using the prefilled syringe only.
- Inject into the thigh, abdomen (avoiding 2 inches around the navel), or upper arm (caregiver-administered only)
- Rotate injection sites with each dose; never inject into skin that is sore, bruised, damaged, or scarred
- Allow Adbry to come to room temperature before injecting (30 minutes for prefilled syringes, 45 minutes for autoinjectors)
- If you miss a dose, take it as soon as you can and then return to your regular schedule
🤒Side effects — in detail▾
The most common side effects reported in clinical trials of Adbry include:
- Upper respiratory tract infections — such as common cold, sore throat, or runny nose
- Conjunctivitis (pink eye) or allergic conjunctivitis — more common with Adbry than with placebo
- Injection site reactions — pain, redness, or swelling where the shot was given
- Eosinophilia — a temporary increase in eosinophils (a type of immune cell) in the blood, which typically returns to normal with continued treatment
- Keratitis or keratoconjunctivitis — inflammation involving the cornea (the clear front of the eye), reported less commonly
Tell your doctor right away if you have eye pain, discharge, or vision changes, or if you have signs of a serious allergic reaction such as facial swelling, hives, or difficulty breathing — these need prompt medical attention.
⚠️Warnings & precautions▾
- Serious allergic reactions: Anaphylaxis (a severe, life-threatening allergic reaction) and angioedema (severe swelling under the skin) have occurred with Adbry. Stop the injection and get emergency help immediately if this happens.
- Eye problems: Conjunctivitis and keratitis (inflammation of the cornea) were reported more often with Adbry than placebo. Report any new or worsening eye symptoms to your doctor promptly.
- Parasitic infections: Adbry may affect your immune response to parasitic worm (helminth) infections. Any pre-existing helminth infection should be treated before starting Adbry. If you develop one while on Adbry and it doesn't respond to treatment, Adbry may need to be paused.
- Live vaccines: Avoid live vaccines during treatment with Adbry. Make sure all recommended vaccinations are up to date before you start.
🔀What it interacts with▾
Adbry has a limited drug interaction profile, but there are important points to keep in mind:
- Live vaccines: Adbry may impair your immune response to live vaccines, increasing the risk of infection — avoid them during treatment
- Non-live vaccines: Studies showed normal antibody responses to tetanus, diphtheria, pertussis, and meningococcal vaccines during Adbry treatment — but data on other non-live vaccines are limited
- Common medications metabolized by the liver (CYP450 enzymes): Adbry did not significantly affect the blood levels of warfarin, omeprazole, metoprolol, midazolam, or caffeine — no dose adjustments expected for these drugs
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- Known allergy: Do not use Adbry if you have had a serious allergic reaction to tralokinumab-ldrm or any ingredient in the product
- Parasitic (worm) infections: Tell your doctor if you have or recently had a helminth infection — it should be treated before starting Adbry
- Vaccines: Get all age-appropriate vaccinations up to date before starting; avoid live vaccines while on Adbry
- Pregnancy: Limited human data are available. Like other antibody medications, Adbry may cross the placenta, especially late in pregnancy. A pregnancy registry exists — call 1-877-311-8972 if you become pregnant while taking Adbry
- Breastfeeding: It is unknown whether tralokinumab-ldrm passes into breast milk. Discuss the risks and benefits with your doctor
- Children under 12: Safety and effectiveness have not been established in patients younger than 12 years of age
- Adults 65 and older: Clinical trial data in older adults are limited; no specific dose adjustment is recommended, but discuss with your prescriber
- Kidney or liver problems: No dose adjustment is needed for mild-to-moderate kidney impairment or mild liver impairment. The effect of severe kidney disease or moderate-to-severe liver disease on Adbry levels is not fully known — tell your doctor
🚑If you take too much▾
There is no specific treatment for an Adbry overdose. If you think you or someone else has received too much, call Poison Control at 1-800-222-1222 right away for guidance. Watch for any signs of side effects and seek medical care promptly if symptoms appear.
📡Pharmacodynamics — effects in the body▾
Adbry works by reducing the activity of inflammatory pathways involved in atopic dermatitis. In clinical studies, treatment with Adbry was associated with decreased blood levels of Th2 and Th22 inflammatory markers — including TARC/CCL17, periostin, IL-22, and IgE — all of which are elevated in eczema. It also reduced signs of abnormal skin cell activity in affected skin and helped restore expression of proteins important for healthy skin barrier function. The full clinical meaning of all these changes is still being studied.
🔬Pharmacokinetics — how your body processes it▾
After a subcutaneous injection, tralokinumab-ldrm is absorbed gradually, with peak blood levels reached about 5 to 8 days after dosing. Its bioavailability (the fraction that actually enters circulation) is estimated at 76%. The drug has a half-life of about 3 weeks, meaning it takes roughly that long for the body to clear half the dose. It is broken down by the body into small peptides through normal protein breakdown pathways — not through the liver's CYP enzyme system. Steady, stable blood levels are reached by about week 16 of treatment. Body weight affects exposure: people weighing more than 100 kg may have somewhat lower drug levels and may need a different dosing schedule.
📦How to store it▾
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. store above 30°C (86°F). refrigerator after reaching room temperature.
📄 Written from Tralokinumab-ldrm injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
Supplements & herbs that interact with Tralokinumab-ldrm injection
53 supplements and herbal products have documented interactions with Tralokinumab-ldrm injection in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Moderate · 52
- Minor · 1
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Tralokinumab-ldrm injection — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly is Adbry and how is it different from my usual eczema creams? ▾
How often do I need to inject Adbry, and can I do it myself at home? ▾
What side effects should I actually expect, and which ones should make me call my doctor? ▾
Do I need to do anything special with vaccines while I'm on Adbry? ▾
Is Adbry safe to use if I'm pregnant or trying to get pregnant? ▾
How do I store and prepare Adbry before I inject it? ▾
Is Tralokinumab-ldrm injection available over the counter? ▾
When was Tralokinumab-ldrm injection first available? ▾
💬 Answers drafted from Tralokinumab-ldrm injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Tralokinumab-ldrm injection comes
Tralokinumab-ldrm injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Adbry is used to treat moderate-to-severe atopic dermatitis in adults when topical prescription therapies have not worked well enough or are not advisable
- Adbry is used to treat moderate-to-severe atopic dermatitis in adolescents 12 to 17 years of age when topical prescription therapies have not worked well enough or are not advisable
- Adbry can be used with or without topical corticosteroids
- Adbry is injected under the skin (subcutaneously) into the thigh, abdomen, or upper arm — do not inject into skin that is tender, damaged, bruised, or scarred
- Adbry prefilled syringes are approved for use in adults and adolescents 12 and older; the Adbry autoinjector is for adults only
- For adolescents 12 and older, Adbry should be given by or under the supervision of an adult
- Before injecting, remove Adbry from the refrigerator and allow it to reach room temperature — at least 30 minutes for prefilled syringes and at least 45 minutes for autoinjectors
📊 Tralokinumab-ldrm injection across the U.S. market
How Tralokinumab-ldrm injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
📈 How widely Tralokinumab-ldrm injection is used
A general measure of how commonly Tralokinumab-ldrm injection is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Tralokinumab-ldrm injection is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Tralokinumab-ldrm injection prescribed? Of the 1,597 medications we measure, Tralokinumab-ldrm injection ranks #807 by Medicaid prescriptions — more than 49% of them.
Utilization by Tralokinumab-ldrm injection product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
2 ML tralokinumab-ldrm 150 MG/ML Auto-Injector Most dispensed
Summed across the 2 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2686061
1 ML tralokinumab-ldrm 150 MG/ML Prefilled Syringe
Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2589378
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Tralokinumab-ldrm injection, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 4 of 11 listed Tralokinumab-ldrm injection NDCs with Medicaid activity.
🔍 Compare Tralokinumab-ldrm injection products
A representative set of FDA-listed product records for Tralokinumab-ldrm injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 150 mg/mL | Subcutaneous | LEO Pharma Inc. × 3 listings | BLA | View NDC → |
| 300 mg/2 mL | Subcutaneous | LEO Pharma Inc. | BLA | View NDC → |
Showing 4 of 4 products — FDA National Drug Code Directory. See every product, package size and price: browse all 4 Tralokinumab-ldrm injection NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Tralokinumab-ldrm injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Tralokinumab-ldrm injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Tralokinumab-ldrm injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 2589225 2 dose forms · 2 strengths
-
Dose form (SCDF) Auto-Injector RxCUI 2686059In current FDA listingsClinical drug / strength (SCD) 2 ML tralokinumab-ldrm 150 MG/MLRxCUI 2686061 -
Dose form (SCDF) Prefilled Syringe RxCUI 2589377No current FDA listingClinical drug / strength (SCD) 1 ML tralokinumab-ldrm 150 MG/MLRxCUI 2589378
Look up RxCUI 2589225 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Tralokinumab-ldrm injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Tralokinumab-ldrm injection belongs to the Interleukin-13 Antagonist class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 1 FDA-filed SPL label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. LEO Pharma Inc. is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.